Inhibiting Phosphatidylcholine Remodeling in Adipose Tissue Increases Insulin Sensitivity

Area of Science:

• Metabolic disorders
• Cellular lipid metabolism
• Insulin signaling

Background:

• Lysophosphatidylcholine acyltransferase (LPCAT) regulates cell membrane phosphatidylcholine (PC) composition.
• Altered membrane PC saturation is linked to metabolic disorders, including insulin resistance.

Purpose of the Study:

• To investigate the role of LPCAT3, the major LPCAT isoform in adipose tissue, in regulating lipid metabolism and insulin signaling.
• To determine the therapeutic potential of targeting LPCAT3 for insulin resistance.

Main Methods:

• Generation of adipocyte-specific Lpcat3-knockout mice.
• Transcriptome sequencing and plasma adipokine profiling.
• In vitro studies using mature human and mouse adipocytes.

Main Results:

• LPCAT3 deficiency in adipocytes reduced polyunsaturated PCs, enhanced insulin sensitivity, and improved insulin receptor and AKT activation.
• LPCAT3 deficiency attenuated diet-induced insulin resistance.
• Elevated LPCAT3 activity in adipose tissue from obese and diabetic models correlated with reduced insulin signaling.
• In vitro addition of polyunsaturated PCs impaired insulin signaling in adipocytes.

Conclusions:

• LPCAT3 plays a critical role in regulating adipose tissue insulin sensitivity through modulation of membrane phospholipid saturation.
• Targeting LPCAT3 in adipose tissue represents a novel therapeutic strategy for combating insulin resistance and metabolic disorders.